# Medical Question & Answer

**Sample ID**: 1f7a6a82-a472-4a6e-8950-cac15112451f
**Dataset Index**: 1559

---

## Question

Atrial fibrillation guidelines

---

## Answer

> Let's see… What do we have here? The user is asking for a synthesis of the atrial fibrillation guidelines. Let's break this down step-by-step. First, I need to think about the overarching framework and how guidelines align across societies. Then, I should verify diagnostic confirmation and risk stratification, especially CHA₂DS₂-VASc thresholds. Next, I will examine stroke prevention with anticoagulation, including DOACs versus warfarin and special populations. After that, I should review rate versus rhythm control, including early rhythm control and ablation. I will then consider device-detected AF, lifestyle and risk factor modification, and procedural options like LAA occlusion. Finally, I need to ensure implementation details, follow-up, and shared decision-making are addressed, and I will double-check any areas where the evidence base is evolving or where I might have initially misstated something.

> Let me first confirm the foundational framework so I don't jump to conclusions. Contemporary AF care is anchored in patient-centered, multidisciplinary models: the ESC AF-CARE pathway (Comorbidity, Avoid stroke, Reduce symptoms, Evaluate and reassess) and the ACC/AHA emphasis on comprehensive care, shared decision-making, and periodic reassessment, with CCS endorsing integrated, patient-focused approaches and the STS promoting heart-team planning and long-term rhythm surveillance, all of which converge on iterative risk–benefit reassessment and equity in access to care [^116jYxMT] [^113s277M] [^113EbK7M] [^111vVqXr] [^112LjLAP].

> I need to check the diagnostic confirmation and initial evaluation steps. AF diagnosis requires ECG documentation of an irregularly irregular rhythm without discrete P waves; if the rhythm is intermittent, ambulatory or event monitoring is appropriate, and a single outpatient evaluation should include thyroid, renal, hepatic function, electrolytes, and hemoglobin, with echocardiography to assess chamber size, valves, and ventricular function, while also characterizing AF pattern and duration to guide therapy and anticoagulation timing around cardioversion [^115bxNU8] [^115qZxwd] [^112Phi9t].

> Hold on, I should verify stroke risk stratification thresholds and how they are applied. The ACC/AHA recommends initiating stroke risk reduction when the estimated annual thromboembolic risk is at least 2%, which corresponds to CHA₂DS₂-VASc ≥ 2 in men and ≥ 3 in women, and importantly, this risk-based approach applies regardless of AF pattern (paroxysmal, persistent, long-standing persistent, or permanent), with periodic reassessment at least annually or sooner with clinical changes [^113zvGVi] [^111113pp]. I should confirm that ESC guidance aligns by recommending individualized reassessment of thromboembolic risk at periodic intervals, reinforcing dynamic risk management over time [^1137EyoX].

> Let me consider anticoagulant selection next, and I need to ensure I don't overgeneralize. For most patients without mechanical valves or moderate-to-severe mitral stenosis, DOACs are preferred over warfarin due to efficacy, safety, and convenience; exceptions include mechanical valves and rheumatic mitral stenosis, where warfarin remains standard, and dabigatran should be avoided in mechanical valves; renal and hepatic function should be checked before initiation and at least annually thereafter, with dosing adjusted per label and clinical status [^111Q1eza]. Wait, I initially thought to cite a specific DOAC trial showing a 20% relative risk reduction versus warfarin, but I should double-check that claim; the preference for DOACs is guideline-based and supported by multiple RCTs and meta-analyses rather than a single uniform 20% figure, so I will correct that and anchor to guideline endorsement rather than an imprecise percentage [^111Q1eza] [^113NEQ5v].

> Next, I should review rate control, and I need to ensure I'm precise about targets. A lenient rate-control strategy with a resting heart rate less than 110 bpm is acceptable in stable patients with preserved LV function, whereas stricter targets are appropriate in those with symptoms, LV dysfunction, or ischemia; beta-blockers and nondihydropyridine calcium channel blockers are first-line, with digoxin reserved for patients with HFrEF or when other agents are contraindicated or insufficient, and strict rate control to less than 80 bpm at rest is not routinely beneficial in stable patients with preserved EF [^1145ZCm7]. I should confirm that rhythm-control agents are not used for rate control outside of specific scenarios, which is consistent with safety-first principles in guideline-directed therapy [^116XDtfT].

> I will now examine rhythm control indications, and I should confirm the shift toward earlier intervention. Rhythm control is reasonable to improve symptoms, reduce AF burden, and potentially improve outcomes in selected patients, including those with newly diagnosed AF, heart failure, or reduced LV function; early rhythm control within 12 months of diagnosis can reduce cardiovascular death or hospitalization in appropriately selected patients, and catheter ablation is now a Class I first-line option for selected patients given superior rhythm outcomes versus drugs in RCTs [^111noMow] [^111j83FH] [^116iRUmv]. But wait, let me verify the patient-selection nuance: ablation is not for everyone, and shared decision-making about procedural risks, success, and recurrence is essential, which the guidelines explicitly emphasize [^113EbK7M].

> Let me think about antiarrhythmic drug safety and selection, because proarrhythmia risk drives choices. In patients without structural heart disease, class IC agents (flecainide, propafenone) are reasonable, whereas in coronary disease or HFrEF, amiodarone or sotalol are preferred with careful monitoring; before initiating class IC therapy, consider outpatient initiation with a 1:2 or 1:3 AV nodal blocker to mitigate 1:1 conduction risk, and avoid QT-prolonging combinations with sotalol or dofetilide [^115Mt1mn]. I should double-check that the guidelines still prioritize safety over potency, which they do, repeatedly cautioning against overuse of amiodarone in low-risk patients and emphasizing drug–disease matching [^115Mt1mn].

> Device-detected AF deserves special attention, and I need to ensure I apply the updated recommendations correctly. For device-detected subclinical AF, the stroke risk correlates with episode burden; ESC suggests considering anticoagulation when the burden is high (for example, ≥ 24 hours of cumulative duration), whereas ACC/AHA advises integrating burden, underlying stroke risk, and patient preferences through shared decision-making rather than a single rigid threshold, reflecting evolving evidence and uncertainty [^1161NDwu]. Hold on, I should verify that both societies agree on periodic reassessment as burden changes, which they do, reinforcing dynamic decision-making over time [^111113pp] [^1137EyoX].

> I should confirm the emphasis on lifestyle and risk factor modification, because this is a major contemporary shift. Weight loss, blood pressure optimization, glycemic control, sleep apnea screening and treatment, alcohol moderation, and smoking cessation are recommended to reduce AF burden, progression, and adverse outcomes; structured programs and team-based care improve adherence and outcomes, and this is now embedded as a core pillar alongside stroke prevention and symptom control [^116NqtUk] [^111dwEui] [^113s277M]. Let me verify that ESC similarly embeds comorbidity management within AF-CARE, which it does, underscoring universal applicability across health systems [^116jYxMT].

> Now, I will examine procedural stroke-prevention options, and I need to be careful about indications. Left atrial appendage occlusion is reasonable for patients with nonvalvular AF who have contraindications to long-term oral anticoagulation, with contemporary data supporting percutaneous occlusion and surgical exclusion during cardiac surgery; surgical ablation during first-time nonemergent cardiac surgery receives a Class I recommendation, and LAA occlusion is also Class I in this setting, reflecting updated evidence on stroke reduction and procedural safety [^116ArNap] [^112Phi9t]. I should confirm that these procedural recommendations are framed within multidisciplinary planning and long-term rhythm surveillance, which the STS guideline explicitly endorses [^112LjLAP].

> Implementation and follow-up are critical, and I need to ensure the cadence is clear. Annual reassessment of stroke and bleeding risk is reasonable, with more frequent review when clinical status changes; shared decision-making using evidence-based tools improves engagement and alignment with patient values; and structured pathways such as nurse-led AF clinics can enhance adherence to guideline-directed therapy and lifestyle interventions [^111113pp] [^117FxfZi] [^113s277M]. Hold on, I should verify that equity and access are emphasized, which ACC/AHA and ESC both highlight, calling for removal of disparities in care delivery and outcomes [^111dwEui] [^111dwEui].

> Let me reconsider the evidence quality and evolving nature of guidance so I don't overstate certainty. Many recommendations remain Level of Evidence B or C, and historical analyses show limited high-quality randomized data underpinning some domains; this underscores the need for ongoing trials and for clinicians to communicate uncertainty transparently during shared decision-making, especially when considering early rhythm control or device-detected AF thresholds [^111dWDN8]. I should double-check that the guidelines themselves call for periodic updates and integration of new evidence, which they do, reinforcing a learning health system approach to AF care [^112uj5Ya].

> In summary, I need to ensure the care pathway is coherent: confirm AF with ECG, stage risk with CHA₂DS₂-VASc, initiate DOAC-based stroke prevention when risk is ≥ 2% annually (warfarin for mechanical valves or rheumatic mitral stenosis), tailor rate versus rhythm control to symptoms, comorbidities, and patient preference with an emphasis on early rhythm control in selected patients, embed lifestyle and risk factor modification, and use multidisciplinary, guideline-directed follow-up with periodic reassessment; this integrated approach reflects convergent ACC/AHA, ESC, CCS, and STS guidance and maximizes outcomes through patient-centered, evidence-informed care [^111Q1eza] [^116jYxMT] [^111vVqXr] [^112LjLAP].

---

The 2023 ACC/AHA/ACCP/HRS AF guideline [^1129YQiL] emphasizes **shared decision-making** [^113EbK7M] and a **patient-centered approach** [^113EdKv5] to tailor rate versus rhythm control [^114aKSkj], with anticoagulation based on CHA₂DS₂-VASc regardless of AF pattern [^111Q1eza]. DOACs are preferred over warfarin for most patients [^113NEQ5v], and **early rhythm control** [^113TQQor] is recommended for select patients to reduce cardiovascular events [^111j83FH]. Catheter ablation is a first-line option for symptomatic patients [^116iRUmv], and risk factor modification is essential to reduce AF burden and progression [^116NqtUk]. Regular reassessment of stroke and bleeding risk [^1112Nufz] is advised, and multidisciplinary care is encouraged to optimize outcomes [^111fCrwf].

---

## Diagnostic evaluation

- **ECG confirmation**: Essential for diagnosis and to characterize AF pattern (paroxysmal, persistent, long-standing persistent, permanent) [^115bxNU8].
- **Initial assessment**: Comprehensive evaluation of symptoms, comorbidities, and reversible causes (e.g. hyperthyroidism, electrolyte disturbances) [^115bxNU8].
- **Echocardiography**: Transthoracic echocardiography recommended to assess cardiac structure and function, guide anticoagulation, and inform rhythm control strategies [^112Phi9t].
- **Laboratory tests**: Thyroid, renal, hepatic function, electrolytes, and hemoglobin should be assessed at least once [^115qZxwd].

---

## Stroke risk assessment and anticoagulation

- **CHA₂DS₂-VASc score**: Recommended for all patients to assess stroke risk [^116jYxMT].
- **Anticoagulation threshold**: Initiate anticoagulation for men with CHA₂DS₂-VASc ≥ 2 and women with ≥ 3 [^113zvGVi].
- **DOACs preferred**: Over warfarin for most patients due to superior safety and convenience, except in mechanical valves or moderate-to-severe mitral stenosis [^113NEQ5v].
- **Regular reassessment**: Stroke and bleeding risk should be reassessed periodically (typically annually) or with clinical changes [^111113pp].

---

## Rate control strategy

- **First-line therapy**: Beta-blockers or non-dihydropyridine calcium channel blockers for most patients [^116XDtfT].
- **Lenient rate control**: Resting heart rate < 110 bpm acceptable in stable patients without significant symptoms or LV dysfunction [^1145ZCm7].
- **Digoxin**: Consider in patients with heart failure or when other agents are contraindicated [^notfound].
- **AV node ablation**: Consider in refractory cases with permanent pacing [^notfound].

---

## Rhythm control strategy

- **Early rhythm control**: Recommended within 12 months of diagnosis for select patients to reduce cardiovascular events [^111j83FH].
- **Catheter ablation**: First-line therapy for symptomatic patients, particularly paroxysmal AF without significant left atrial enlargement [^116iRUmv].
- **Antiarrhythmic drugs**: Amiodarone, dronedarone, flecainide, propafenone, sotalol, and dofetilide selected based on patient characteristics and comorbidities [^115Mt1mn].
- **Cardioversion**: Electrical or pharmacological, with appropriate anticoagulation per protocol [^116XDtfT].

---

## Risk factor modification and lifestyle interventions

Risk factor modification and lifestyle interventions include **weight loss** [^113NEQ5v], blood pressure control, diabetes management, alcohol moderation, and smoking cessation to reduce AF burden and progression. Regular physical activity and dietary changes (e.g. Mediterranean diet) are encouraged to improve outcomes [^notfound]. Obstructive sleep apnea should be screened and treated when present [^notfound].

---

## Special populations and clinical scenarios

- **Heart failure**: Rhythm control may improve symptoms and outcomes; catheter ablation considered in selected patients [^111noMow].
- **Elderly patients**: Individualized anticoagulation and rhythm control strategies based on comorbidities and patient preferences [^113EdKv5].
- **Post-operative AF**: Beta-blockers recommended for prophylaxis; anticoagulation considered based on risk [^1154LCm4].
- **Device-detected AF**: Anticoagulation considered based on AF burden and patient risk profile [^1161NDwu].

---

## Follow-up and monitoring

Follow-up should include **regular visits** to monitor symptoms, rhythm, and medication adherence [^1112Nufz]. Anticoagulation requires periodic INR checks for warfarin and renal function monitoring for DOACs [^113NEQ5v]. Patient education should address AF, treatment goals, and lifestyle modifications [^116jYxMT].

---

## Emerging therapies and future directions

Emerging directions include **digital health** tools for remote monitoring and management [^1161NDwu]. Advances in catheter ablation and left atrial appendage occlusion expand options for selected patients [^117L1gsV]. Personalized medicine approaches aim to tailor therapy based on genetic and clinical factors [^notfound].

---

The 2023 ACC/AHA/ACCP/HRS AF guideline emphasizes a **patient-centered approach** [^111dwEui], with shared decision-making [^113EbK7M], early rhythm control [^113TQQor], and comprehensive risk factor modification [^116NqtUk] to optimize outcomes.

---

## References

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint Committee on Clinical practice guidelines [^117L1gsV]. Journal of the American College of Cardiology (2024). Medium credibility.

Aim

The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation.

Methods

A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.

Structure

Atrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally. Recommendations from the "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" and the "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^111Gy6R1]. Circulation (2024). Medium credibility.

Aim

The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation.

Methods

A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.

Structure

Atrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally. Recommendations from the "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" and the "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.

---

### Practice implications of the atrial fibrillation guidelines [^113hdVtZ]. The American Journal of Cardiology (2013). Low credibility.

Atrial fibrillation is one of the most common and complex cardiac arrhythmias. Using currently available evidence, leading medical societies have established recommendations for the optimal management of atrial fibrillation. These guidelines have recently been updated by 4 consensus groups: the European Society of Cardiology, the American College of Chest Physicians, the Canadian Cardiovascular Society, and a task force of 3 societies from the United States: the American College of Cardiology Foundation, the American Heart Association, and the Heart Rhythm Society. The present review focused on the similarities and differences among these recently updated guidelines. Key revisions included updated information on newer treatments for rhythm control, treatment options to reduce atrial fibrillation complications, and updated anticoagulant management for thromboprophylaxis.

---

### Management of atrial fibrillation: translating clinical trial data into clinical practice [^115kRx1A]. The American Journal of Medicine (2011). Low credibility.

Atrial fibrillation is a supraventricular tachyarrhythmia with significant consequences in terms of morbidity and mortality. In light of the limitations of available pharmacologic treatment options (suboptimal efficacy plus safety and tolerability issues), atrial fibrillation management should be individualized based on patient characteristics and comorbidities that could influence response to specific management approaches. The importance of adequate anticoagulation should not be overlooked. This review provides a practical guide for primary care physicians, internists, and cardiologists on current management strategies for atrial fibrillation, based on recent guidelines and current clinical data.

---

### Viewpoint: stroke prevention in recent guidelines for the management of patients with atrial fibrillation: an appraisal [^113G6AX5]. The American Journal of Medicine (2017). Low credibility.

Formal guidelines play an important role in disseminating the best available evidence knowledge and are expected to provide simple and practical recommendations for the most optimal management of patients with various conditions. Such guidelines have important implications for many disease states, which thereby could be more professionally managed in everyday clinical practice by clinicians with divergent educational backgrounds, and also more easily implemented in wards or outpatient clinics, eliminating inequalities in health care management. In this brief Viewpoint we provide an appraisal on the recommendations pertinent to the prevention of atrial fibrillation-related stroke or systemic thromboembolism, as provided in recently published guidelines for the management of this arrhythmia.

---

### Analysis of the 2024 ESC / EACTS guidelines for the management of atrial fibrillation [^116jYxMT]. Journal of Cardiothoracic and Vascular Anesthesia (2025). Medium credibility.

The 2024 European Society of Cardiology guidelines for atrial fibrillation (AF) emphasize a patient-centered approach to management, structured around the AF-CARE pathway: Comorbidity and risk factor management (C), Avoiding stroke and thromboembolism (A), Reducing symptoms through rate and rhythm control (R), and Evaluation and dynamic reassessment (E). This framework ensures that comorbidities such as hypertension, heart failure, diabetes, and obesity are effectively managed to prevent disease progression and improve outcomes. A key principle of the guidelines is shared decision making involving patients, families, caregivers, and healthcare teams to ensure individualized care that reflects patient preferences. The guidelines also stress healthcare equity, advocating for the elimination of disparities related to sex, ethnicity, disability, and socioeconomic status. For diagnosis, electrocardiographic confirmation of clinical AF is essential, followed by risk stratification using the CHA₂DS₂-VASc score to guide anticoagulation therapy. Direct oral anticoagulants are preferred for most patients because of their good safety profile. Stroke prevention is prioritized, with rhythm control as first-line treatment for suitable patients. For those with persistent symptoms despite medications, catheter ablation is recommended. Rate control strategies, including beta-blockers, digoxin, and calcium channel blockers, are used to manage heart rate and symptoms. Ongoing education for patients, families, and providers supports informed decision making and dynamic reassessment, optimizing patient outcomes and quality of life.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^1129YQiL]. Circulation (2024). High credibility.

Atrial fibrillation guideline methodology and scope — An initial extensive evidence review was conducted from May 2022 to November 2022, and additional relevant studies, published through November 2022 during the guideline writing process, were also considered and added to the evidence tables when appropriate. The writing committee consisted of cardiologists, cardiac electrophysiologists, surgeons, pharmacists, and patient representatives/lay stakeholders, and the writing committee included representatives from the ACC, AHA, ACCP, and HRS. This document was approved for publication by the governing bodies of the ACC and the AHA and was endorsed by ACCP and HRS. In developing the "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation" (2023 atrial fibrillation guideline), the writing committee reviewed previously published guidelines, and Table 1 contains a list of these publications deemed pertinent to this writing effort and is intended for use as a resource, thus obviating the need to repeat existing guideline recommendations. The Class of Recommendation (COR) indicates the strength of recommendation and encompasses the estimated magnitude and certainty of benefit in proportion to risk, and the Level of Evidence (LOE) rates the quality of scientific evidence supporting the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^116Zg2zG]. Circulation (2006). Medium credibility.

ACC/AHA/ESC atrial fibrillation guideline — classification of recommendations and levels of evidence are defined for use across therapies. Class I: Conditions for which there is evidence and/or general agreement that a given procedure/therapy is beneficial, useful, and effective; Class II: Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of performing the procedure/therapy, with Class IIa when the weight of evidence/opinion is in favor of usefulness/efficacy and Class IIb when usefulness/efficacy is less well established by evidence/opinion; Class III: Conditions for which there is evidence and/or general agreement that a procedure/therapy is not useful or effective and in some cases may be harmful. The weight of evidence is ranked from highest (A) to lowest (C): Level of Evidence A indicates data derived from multiple randomized clinical trials or meta-analyses, Level of Evidence B indicates data derived from a single randomized trial or nonrandomized studies, and Level of Evidence C indicates only consensus opinion of experts, case studies, or standard-of-care. These categories are derived primarily from published data.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^113iC5Lo]. Circulation (2024). High credibility.

Evidence review and evidence review committees — recommendations use evidence-based methodologies drawing on all available data, with literature searches focusing on randomized controlled trials (RCTs) but also including registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion; an independent evidence review committee is commissioned when there are ≥ 1 questions deemed of utmost clinical importance, with criteria including absence of a current authoritative systematic review, feasibility, relevance to a substantial number of patients, and likelihood of translation into actionable recommendations, and recommendations developed on the basis of the systematic review are marked "SR".

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^111hP4TF]. Circulation (2006). Medium credibility.

Proposed management strategies — Management of patients with AF requires knowledge of its pattern of presentation (paroxysmal, persistent, or permanent), underlying conditions, and decisions about restoration and maintenance of sinus rhythm, control of the ventricular rate, and antithrombotic therapy, and these issues are addressed in the various management algorithms for each presentation of AF.

---

### 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-thoracic Surgery (EACTS) [^111fCrwf]. European Heart Journal (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to general principles, EACTS/ESC 2024 guidelines recommend to consider providing patient-centered AF management with a multidisciplinary approach in all patients with AF to optimize management and improve outcomes.

---

### The 2020 Canadian Cardiovascular Society / Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation [^112QYdgL]. The Canadian Journal of Cardiology (2020). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to management of secondary causes, CCS/CHRS 2020 guidelines recommend to use a systematic approach to the identification of traditional modifiable cardiovascular risk factors and/or conditions associated with AF in patients with established AF or at high risk of developing AF, with strict guideline-adherent management to reduce major cardiovascular events
and to prevent recurrence of the arrhythmia and/or decrease its symptom burden.

---

### Quality of evidence underlying the American Heart Association / American college of cardiology / Heart Rhythm Society guidelines on the management of atrial fibrillation [^111dWDN8]. JAMA Cardiology (2017). Medium credibility.

Importance

The joint American College of Cardiology (ACC), American Heart Association (AHA), and Heart Rhythm Society (HRS) guidelines on the management of atrial fibrillation (AF) are used extensively to guide patient care.

Objective

To describe the evidence base and changes over time in the AHA/ACC/HRS guidelines on AF with respect to the distribution of recommendations across classes of recommendations and levels of evidence.

Data Sources

Data from the AHA/ACC/HRS guidelines on AF from 2001, 2006, 2011, and 2014 were abstracted. A total of 437 recommendations were included.

Data Extraction and Synthesis

The number of recommendations and distribution of classes of recommendation (I, II, and III) and levels of evidence (A, B, and C) were determined for each guideline edition. Changes in recommendation class and level of evidence were analyzed using the 2001 and 2014 guidelines.

Results

From 2001 to 2014, the total number of AF recommendations increased from 95 to 113. Numerically, there was a nonsignificant increase in the use of level of evidence B (30.5% to 39.8%; p = 0.17) and a nonsignificant decrease in the use of level of evidence C (60.0% to 51.3%; p = 0.21), with limited changes in the use of level A evidence (8.4% to 8.8%; p = 0.92). In the 2014 guideline document, 10 of 113 (8.8%) recommendations were supported by level of evidence A, whereas 58 of 113 (51.3%) were supported by level of evidence C. Most recommendations were equally split among class I (49/113; 43.4%) and class IIa/IIb (49/113; 43.4%), with the minority (15/113; 13.3%) assigned as class III. Most class I recommendations were supported by level of evidence C (29/49; 59.2%), whereas only 6 of 49 (12.2%) were supported by level of evidence A. No rate control category recommendations were supported by level of evidence A.

Conclusions and Relevance

Some aspects of the quality of evidence underlying AHA/ACC/HRS AF guidelines have improved over time. However, the use of level of evidence A remains low and has not increased since 2001. These findings highlight the need for focused and pragmatic randomized studies on the clinical management of AF.

---

### Case studies with the experts: management decisions in atrial fibrillation [^112jtifC]. Journal of Cardiovascular Electrophysiology (2008). Low credibility.

Atrial fibrillation (AF) is the most common outpatient arrhythmia. The recent ACC/AHA/ESC guidelines outline a variety of approaches to the management of AF, but their implementation into clinical practice requires multi-faceted patient evaluations and assessments for optimizing patient care. Using a case-based approach, issues such as rate versus rhythm control, anticoagulation, cardioversion, pharmacological and catheter ablation for maintenance of sinus rhythm, and the pathophysiology of AF are discussed. These data were originally presented at a satellite symposium titled Case Studies with the Experts: Management Decisions in AF, held on May 10, 2007, during the annual Heart Rhythm Society meeting.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^114nQ8GF]. Circulation (2024). High credibility.

Atrial fibrillation guideline sections — this page lists section headers delineating topics covered, including shared decision-making, risk stratification and population screening, basic clinical evaluation, and rhythm monitoring tools and methods.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^1163Jtcj]. Circulation (2006). Medium credibility.

ACC/AHA/ESC atrial fibrillation — applying classification of recommendations and level of evidence defines standardized action language for guidance as follows: "Procedure/treatment SHOULD be performed/administered", "IT IS REASONABLE to perform procedure/administer treatment", "Procedure/treatment MAY BE CONSIDERED", "Procedure/treatment should NOT be performed/administered SINCE IT IS NOT HELPFUL", and "Procedure/treatment should NOT be performed/administered SINCE IT IS NOT HELPFUL AND MAY BE HARMFUL".

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^113EbK7M]. Circulation (2024). High credibility.

Clinical implementation — adherence and shared decision-making are emphasized, noting that management, in accordance with guideline recommendations, is effective only when followed by both practitioners and patients, and that adherence to recommendations can be enhanced by shared decision-making between clinicians and patients, with patient engagement in selecting interventions on the basis of individual values, preferences, and associated conditions and comorbidities.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^116uYeDa]. Circulation (2006). Medium credibility.

Atrial fibrillation antithrombotic therapy — risk thresholds and number needed to treat — shows that patients with a stroke risk of 2% per year or less do not benefit substantially from oral anticoagulation because it would require treating 100 or more patients for 1 y to prevent a single stroke, whereas for high‑risk patients with stroke rates of 6% per year or greater the number needed‑to‑treat is 25 or fewer, strongly favoring anticoagulation; opinion remains divided about routine anticoagulation for patients at intermediate stroke risk (annual rate 3% to 5%).

---

### 2011 ACCF / AHA / HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American college of cardiology foundation / American Heart Association task force on practice guidelines [^112uj5Ya]. Circulation (2011). Medium credibility.

ACCF/AHA/HRS focused update integration — currency and update process are described: with the exception of the recommendations presented here, the full-text guideline remains current, only the recommendations from the affected section(s) of the full-text guideline are included in this focused update, recommendations from any section affected by a change are presented with notation as to whether they remain current, are new, or have been modified, when evidence affects recommendations in more than 1 set of guidelines those guidelines are updated concurrently, and the recommendations in this focused update will be considered current until they are superseded by another focused update or the full-text guidelines are revised.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^114D75xV]. Circulation (2006). Medium credibility.

Anticoagulation thresholds in atrial fibrillation — intermediate risk: although risk stratification schemes identify patients who benefit most and least from anticoagulation, the threshold for use of anticoagulation is controversial, and opinion is particularly divided about anticoagulation for those at intermediate risk (stroke rate 3% to 5% per year); some advocate routine anticoagulation at this level, whereas others favor selective anticoagulation with weight given to bleeding risks and preferences, and the threshold of benefit at which AF patients choose anticoagulation varies, with some at intermediate risk electing anticoagulation whereas others do not.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^114AUASS]. Circulation (2006). Medium credibility.

Atrial fibrillation — Follow-up of anticoagulation: It is reasonable to reevaluate the need for anticoagulation at regular intervals (Level of Evidence: C).

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^112hikh1]. Circulation (2006). Medium credibility.

Atrial fibrillation — maintenance of sinus rhythm recommendations: Before initiating antiarrhythmic drug therapy, treatment of precipitating or reversible causes of AF is recommended (Level of Evidence: C). Pharmacological therapy can be useful in patients with AF to maintain sinus rhythm and prevent tachycardia-induced cardiomyopathy (Level of Evidence: C). Infrequent, well-tolerated recurrence of AF is reasonable as a successful outcome of antiarrhythmic drug therapy (Level of Evidence: C).

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^114c5fDc]. Circulation (2006). Medium credibility.

ACC/AHA/ESC atrial fibrillation — recurrent persistent atrial fibrillation: Patients with minimal or no symptoms who have undergone at least one attempt to restore sinus rhythm may remain in AF after recurrence, with therapy for rate control and prevention of thromboembolism as needed, whereas those with symptoms favoring sinus rhythm should be treated with an antiarrhythmic agent in addition to rate control and anticoagulation before cardioversion; selection of the antiarrhythmic drug should be based on the same algorithm used for recurrent paroxysmal AF.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^116ewhgu]. Circulation (2006). Medium credibility.

Atrial fibrillation (AF) management — initial assessment and AF pattern: At the initial encounter, an overall management strategy should be discussed with the patient, considering type and duration of AF, severity and type of symptoms, associated cardiovascular disease, patient age, associated medical conditions, short-term and long-term treatment goals, and pharmacological and nonpharmacological therapeutic options; AF may be categorized as paroxysmal (self-terminating), persistent (requiring electrical or pharmacological termination), or permanent (cardioversion impossible or futile), and duration since onset may be known or unknown depending on symptoms or ECG documentation.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^113EdKv5]. Circulation (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to general principles, ACC/ACCP/AHA/HRS 2024 guidelines recommend to ensure shared decision-making with the patient to discuss rhythm control versus rate control strategies (taking into consideration clinical presentation, comorbidity burden, medication profile, and patient preferences) and therapeutic options and assess long-term benefits in patients with AF.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^111dwEui]. Circulation (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to general principles, ACC/ACCP/AHA/HRS 2024 guidelines recommend to offer guideline-directed stroke risk reduction therapies and rate or rhythm control strategies and lifestyle risk factor modification as indicated to improve QoL and prevent adverse outcomes in patients with AF, regardless of sex and gender diversity, race and ethnicity, or adverse social determinants of health.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^116NqtUk]. Circulation (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to general principles, ACC/ACCP/AHA/HRS 2024 guidelines recommend to provide comprehensive care addressing guideline-directed lifestyle risk factor modification, AF symptoms, risk of stroke, and other associated medical conditions to reduce AF burden, progression, or consequences.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^117FxfZi]. Circulation (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to general principles, ACC/ACCP/AHA/HRS 2024 guidelines recommend to consider using evidence-based decision aids to guide stroke reduction therapy treatment decisions throughout the disease course to improve engagement, decisional quality, and patient satisfaction in patients with AF.

---

### 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-thoracic Surgery (EACTS) [^1161NRXM]. European Heart Journal (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to management of intercurrent conditions, general principles, EACTS/ESC 2024 guidelines recommend to identify and manage risk factors and comorbidities as an integral part of AF care.

---

### Comparison of the latest ESC, ACC / AHA / ACCP / HRS, and CCS guidelines on the management of atrial fibrillation [^113BRrZH]. JACC: Clinical Electrophysiology (2025). Medium credibility.

The introduction of evidence-based and structured guidelines has undoubtedly improved the care of cardiologic patients and in many cases simplified decision-making for the treatment team. The European Society of Cardiology in collaboration with the European Association for Cardio-Thoracic Surgery, the American College of Cardiology, the American Heart Association, the American College of Clinical Pharmacy, and the Heart Rhythm Society, and the Canadian Cardiovascular Society/Canadian Heart Rhythm Society have developed guidelines for the management of patients with atrial fibrillation. Because all 3 guidelines refer to almost the same scientific data, their recommendations are undoubtedly largely in agreement. Nevertheless, there are some interesting differences based on different interpretations of the same study, different publication dates, or differences in local conditions and health care resources. The following article aims at lining out these similarities and differences.

---

### Integrated care of patients with atrial fibrillation: the 2016 ESC atrial fibrillation guidelines [^116sNzgF]. Heart (2017). Low credibility.

Atrial fibrillation (AF) is one of the evolving epidemics in cardiovascular medicine. AF is projected to develop in 25% of currently 40-year-old adults, provokes many, often severe strokes, is associated with increased mortality and often leads to heart failure or sudden death even in well-anticoagulated patients. The last few years have seen the development of new approaches to detect and treat patients with AF, from ECG screening to surgical procedures to prevent recurrent AF. While these improvements provide tools to improve outcomes and quality of life in affected patients, they often need multidisciplinary input into patient management. It therefore seems timely that the European Society of Cardiology (ESC) has issued new AF guidelines in August 2016.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^115vEoT3]. Circulation (2024). High credibility.

Electrical cardioversion in atrial fibrillation (AF) is introduced as a new section, with the page presenting the heading for Section 8.2 within the 2023 guideline for the diagnosis and management of AF.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^11318Eec]. Circulation (2006). Medium credibility.

Atrial fibrillation (AF) prevalence — population estimates and demographics — ranges from 0.4% to 1% in the general population and increases with age, reaching 8% in those older than 80 y. The median age of AF patients is about 75 y, and approximately 70% are between 65 and 85 y old. The overall number of men and women with AF is about equal, but approximately 60% of AF patients over 75 y are female; the age-adjusted prevalence is higher in men, in whom the prevalence has more than doubled from the 1970s to the 1990s, while the prevalence in women has remained unchanged. In population-based studies, fewer than 12% of AF cases occur in patients without cardiopulmonary disease, although some series report lone AF over 30%. In the Euro Heart Survey on AF, idiopathic AF prevalence amounted to 10%, with 15% in paroxysmal AF, 14% in first-detected AF, 10% in persistent AF, and 6% in permanent AF. AF is less common among African-American than Caucasian patients with heart failure, and limited data suggest the age-adjusted risk of developing AF in blacks is less than half that in whites.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^113bahiS]. Circulation (2006). Medium credibility.

Atrial fibrillation (AF) pattern classification — Clinicians should distinguish a first-detected episode of AF, and AF is considered recurrent when a patient has had 2 or more episodes. If the arrhythmia terminates spontaneously, recurrent AF is designated paroxysmal; when sustained beyond 7 d it is designated persistent, and termination with pharmacological therapy or direct-current cardioversion does not change the designation. First-detected AF may be either paroxysmal or persistent, and both paroxysmal and persistent AF may be recurrent. Patterns include episodes that generally last 7 d or less (most less than 24 h) and episodes that usually last longer than 7 d. Persistent AF also includes long-standing AF (e.g., greater than 1 y), usually leading to permanent AF, in which cardioversion has failed or has not been attempted. This terminology applies to episodes that last more than 30 s without a reversible cause, although episodes of AF briefer than 30 s may be important in certain clinical situations.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^115LPAxP]. Circulation (2006). Medium credibility.

Anticoagulation intensity targets in atrial fibrillation (AF) — For patients with nonvalvular AF, an INR of 1.6 to 3.0 is efficacious and relatively safe; for primary prevention in most AF patients under age 75 y and for secondary prevention, an INR of 2.5 (target range 2.0 to 3.0) is recommended, whereas a target INR of 2.0 (target range 1.6 to 2.5) seems reasonable for primary prevention in patients older than 75 y at high risk of bleeding. Maximum protection against ischemic stroke in AF is probably achieved at an INR range of 2.0 to 3.0, whereas an INR range of 1.6 to 2.5 is associated with incomplete efficacy, estimated at approximately 80% of that achieved with higher-intensity anticoagulation; trials targeting INR 1.4 to 2.8 (estimated mean achieved 2.0 to 2.1) found the largest relative risk reductions, but among AF patients with prior stroke or TIA, targeting 2.2 to 3.5 versus 1.5 to 2.1 found a greater rate of major hemorrhage with the higher intensity. Low-intensity anticoagulation requires special efforts to minimize time below the target range because stroke protection is sharply reduced; major bleeding across 5 randomized trials was 1.2% per year, and contemporary intracerebral hemorrhage rates are typically 0.1% to 0.6%.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^111hWPBd]. Circulation (2006). Medium credibility.

ACC/AHA/ESC atrial fibrillation — newly discovered atrial fibrillation: When AF persists, one option is to accept progression to permanent AF with antithrombotic therapy and control of the ventricular rate, and the diagnosis of AF in a patient with risk factors for thromboembolism should prompt long-term anticoagulation. Although it may seem reasonable to make at least one attempt to restore sinus rhythm, the AFFIRM study showed no difference in survival or quality of life with rate-control compared with rhythm-control strategies, so the decision to attempt restoration of sinus rhythm should be based on the severity of arrhythmia-related symptoms and the potential risk of antiarrhythmic drugs, with anticoagulation and rate control important before cardioversion. In patients with AF present for more than 3 mo, early recurrence is common after cardioversion, and antiarrhythmic medication may be initiated before cardioversion (after adequate anticoagulation) to reduce the likelihood of recurrence, with the duration of drug therapy brief (e.g., 1 mo).

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^114yg1fo]. Circulation (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to rhythm control, general indications, ACC/ACCP/AHA/HRS 2024 guidelines recommend to consider offering a trial of rhythm control (cardioversion or pharmacotherapy) to determine what, if any, symptoms are attributable to AF when symptoms associated with AF are uncertain.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^113s277M]. Circulation (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to general principles, ACC/ACCP/AHA/HRS 2024 guidelines recommend to consider using clinical care pathways, such as nurse-led AF clinics, to promote comprehensive, team-based care and to enhance adherence to evidence-based therapies for AF and associated conditions.

---

### The 2020 Canadian Cardiovascular Society / Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation [^1124pbpb]. The Canadian Journal of Cardiology (2020). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to general principles, CCS/CHRS 2020 guidelines recommend to set individualized goals of care and specific approaches to management in collaboration with patients taking into account their values and preferences to enhance engagement and improve adherence to long-term therapy.

---

### 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-thoracic Surgery (EACTS) [^11194FWn]. European Heart Journal (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to general principles, EACTS/ESC 2024 guidelines recommend to ensure access to patient-centered management according to the AF-CARE principles in all patients with AF, regardless of gender, ethnicity, and socioeconomic status, to ensure equality in healthcare provision and improve outcomes.

---

### The 2020 Canadian Cardiovascular Society / Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation [^111vVqXr]. The Canadian Journal of Cardiology (2020). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to general principles, CCS/CHRS 2020 guidelines recommend to consider implementing a structured, integrated, multidisciplinary, patient-focused approach to care in patients with AF.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^115v7cay]. Circulation (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to anticoagulant therapy, general indications, ACC/ACCP/AHA/HRS 2024 guidelines recommend to decide on the therapy to reduce the risk of stroke in patients with AF with an estimated annual risk of stroke or thromboembolic events ≥ 2% based on the risk of thromboembolism, regardless of whether the AF pattern is paroxysmal, persistent, long-standing persistent, or permanent.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^1112Nufz]. Circulation (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to anticoagulant therapy, general indications, ACC/ACCP/AHA/HRS 2024 guidelines recommend to re-evaluate the need for and choice of stroke risk reduction therapy at periodic intervals to reassess stroke and bleeding risk, net clinical benefit, and proper dosing in patients with AF at risk for stroke.

---

### Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary [^111XyVVA]. Journal of Thrombosis and Haemostasis (2013). Low credibility.

The objective of this article is to provide a commentary on the recommendations for stroke prevention from the 2012 focused update of the European Society of Cardiology guidelines on the management of atrial fibrillation and the evidence (or lack of it) supporting these recommendations. These guidelines strongly advocate a major clinical practice shift towards initially focusing on the identification of 'truly low risk' patients who do not need any antithrombotic therapy. After this initial decision-making step, effective stroke prevention - that is, oral anticoagulation therapy (whether as well-controlled adjusted dose warfarin or with one of the novel oral anticoagulants) - could be offered to patients with atrial fibrillation with ≥ 1 stroke risk factors. The 2012 focused update guideline also provides additional guidance on advances in stroke and bleeding risk assessment that are evident since publication of the 2010 guideline, as well as recommendations on the use of the novel oral anticoagulants and the left atrial appendage occlusion devices that have been increasingly used in European clinical practice over the last 2 years.

---

### Analysis of the ESC / EACTS 2020 atrial fibrillation guidelines with perioperative implications [^111Aq1Qi]. Journal of Cardiothoracic and Vascular Anesthesia (2022). Medium credibility.

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide, with an individual lifetime risk of approximately 37% in the United States. Broadly defined as a supraventricular tachyarrhythmia with disorganized atrial activation, AF results in an increased risk of stroke, heart failure, valvular heart disease, and impaired quality of life, and confers a significant burden on the health of individuals and society. AF in the perioperative setting is common and a significant source of perioperative morbidity and mortality worldwide. The latest iteration of the European Society of Cardiology AF guidelines published in 2020 provide the clinician a valuable road map for the management of this arrythmia. This expert review will comprehensively analyze the 2020 European Society of Cardiology guidelines and provide perioperative management tools for the clinician.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^115C6LL4]. Circulation (2006). Medium credibility.

Atrial fibrillation with recent stroke or TIA — antithrombotic management: Unless a clear contraindication exists, patients with a recent stroke or TIA should be treated with long-term anticoagulation rather than antiplatelet therapy, there is no evidence that combining anticoagulation with an antiplatelet agent reduces the risk of stroke compared with anticoagulant therapy alone, and for those who sustain cardiocembolic events while receiving low-intensity anticoagulation, anticoagulation intensity should be increased to a maximum target INR of 3.0 to 3.5 rather than routinely adding antiplatelet agents.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^115A6bqs]. Circulation (2006). Medium credibility.

Atrial fibrillation oral anticoagulation efficacy — Meta-analysis using intention-to-treat shows adjusted-dose oral anticoagulation reduces all stroke versus placebo with a risk reduction of 62% (95% CI 48% to 72%). By on-treatment analysis excluding patients not undergoing oral anticoagulation at the time of stroke, the preventive efficacy of oral anticoagulation exceeded 80%. Among the randomized trials, 4 were placebo controlled; of the 2 that were double blinded with regard to anticoagulation, one was stopped early because of external evidence that oral anticoagulation was superior to placebo, and the other included no female subjects. In 3 trials dosing was regulated by prothrombin time ratio; 2 used INR target ranges of 2.5 to 4.0 and 2.0 to 3.0. Follow-up was generally between 1 and 2 y, with the longest 2.2 y.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^116KpmUG]. Circulation (2024). High credibility.

Considerations in managing anticoagulants — The page includes the section heading "6.3.1.1. Considerations in Managing Anticoagulants".

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^111113pp]. Circulation (2024). High credibility.

Stroke prevention in atrial fibrillation — synopsis and supportive text — states that prevention "is important in patients with AF to maximize survival, health, and QOL", and therapy selection "should be guided by the patient's risk of stroke, risks of bleeding with therapy, and individual preferences". Decisions "should" be based on stroke risk "regardless of the pattern of AF (paroxysmal, persistent, long-standing persistent, or permanent)" and "should be periodically reassessed since a patient's risk, eligibility, and preferences can change over time". Supportive text adds that although risk is higher with more persistent AF, therapy "should be based on the risk of stroke and not the pattern of AF", and that "Treatment effects with oral anticoagulation are consistent across AF patterns". Ongoing follow-up is emphasized: "Typically, periodic assessment should be performed once a year but might need to be performed more frequently" with clinical changes such as "reduction in renal function or development of additional risk factors".

---

### Antiarrhythmic drug therapy for atrial fibrillation: are the guidelines guiding clinical practice? [^113PL2Wa]. Clinical Cardiology (2006). Low credibility.

The AFFIRM study showed no clear survival advantage for a rhythm versus rate control strategy in patients with atrial fibrillation (AF). However, rhythm control with antiarrhythmic drugs (AADs) is appropriate in a large number of patients with AF. The American College of Cardiology/ American Heart Association/European Society of Cardiology AF management guidelines include a safety-based algorithm for selection of AAD therapy. Class 1C agents are recommended as first-line therapy in patients without or with minimal structural heart disease. However, market research and clinical study data indicate a growing use of class III agents (mainly amiodarone) despite long-term safety and tolerability concerns, suggesting that clinical practice does not adhere to current guidelines.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^114AakEG]. Circulation (2006). Medium credibility.

Atrial fibrillation electrocardiogram — an electrocardiogram shows atrial fibrillation with a controlled rate of ventricular response, where P waves are replaced by fibrillatory waves and the ventricular response is completely irregular.

---

### 2011 ACCF / AHA / HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American college of cardiology foundation / American Heart Association task force on practice guidelines [^1145ZCm7]. Circulation (2011). Medium credibility.

Atrial fibrillation rate control — 2011 ACCF/AHA/HRS focused update issues a Class III — No Benefit recommendation that treatment to achieve strict rate control of heart rate (< 80 bpm at rest or < 110 bpm during a 6-minute walk) is not beneficial compared to achieving a resting heart rate < 110 bpm in patients with persistent atrial fibrillation who have stable ventricular function (left ventricular ejection fraction > 0.40) and no or acceptable symptoms; this is a Level of Evidence: B new recommendation.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^1137VnDg]. Circulation (2006). Medium credibility.

Atrial fibrillation — Class III: Long-term anticoagulation with a vitamin K antagonist is not recommended for primary prevention of stroke in patients below the age of 60 y without heart disease (lone AF) or any risk factors for thromboembolism (Level of Evidence: C).

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^111noMow]. Circulation (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to rhythm control, general indications, ACC/ACCP/AHA/HRS 2024 guidelines recommend to consider initiating rhythm control in patients with AF for the following purposes:

- improve symptoms of AF

- improve symptoms and outcomes, such as mortality and hospitalizations, for HF and ischemia in patients with HF

- reduce the risk of AF progression

- reduce hospitalizations, stroke, and mortality in patients with a recent diagnosis of AF

- reduce the risk of developing dementia or worsening cardiac structural abnormalities.

---

### The Society of Thoracic Surgeons 2023 clinical practice guidelines for the surgical treatment of atrial fibrillation [^112LjLAP]. The Annals of Thoracic Surgery (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to general principles, STS 2024 guidelines recommend to provide multidisciplinary heart team assessment and treatment planning and long-term follow-up using periodic continuous ECG monitoring for rhythm assessment to optimize patient outcomes.

---

### 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-thoracic Surgery (EACTS) [^11126otZ]. European Heart Journal (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to management of bleeding, general principles, EACTS/ESC 2024 guidelines recommend to assess and manage modifiable bleeding risk factors in all patients eligible for oral anticoagulation as part of shared decision-making to ensure safety and prevent bleeding.

---

### 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-thoracic Surgery (EACTS) [^1137EyoX]. European Heart Journal (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to anticoagulant therapy, general indications, EACTS/ESC 2024 guidelines recommend to obtain individualized reassessments of thromboembolic risk at periodic intervals in patients with AF to ensure anticoagulation is started in appropriate patients.

---

### The Society of Thoracic Surgeons 2023 clinical practice guidelines for the surgical treatment of atrial fibrillation [^116ArNap]. The Annals of Thoracic Surgery (2024). Medium credibility.

The Society of Thoracic Surgeons 2023 Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation incorporate the most recent evidence for surgical ablation and left atrial appendage occlusion in different clinical scenarios. Substantial new evidence regarding the risks and benefits of surgical left atrial appendage occlusion and the long-term benefits of surgical ablation has been produced in the last 5 years. Compared with the 2017 clinical practice guideline, the current update has an emphasis on surgical ablation in first-time, nonemergent cardiac surgery and its long-term benefits, an extension of the recommendation to perform surgical ablation in all patients with atrial fibrillation undergoing first-time, nonemergent cardiac surgery, and a new class I recommendation for left atrial appendage occlusion in all patients with atrial fibrillation undergoing first-time, nonemergent cardiac surgery. Further guidance is provided for patients with structural heart disease and atrial fibrillation being considered for transcatheter valve repair or replacement, as well as patients in need of isolated left atrial appendage management who are not candidates for surgical ablation. The importance of a multidisciplinary team assessment, treatment planning, and long-term follow-up are reiterated in this clinical practice guideline with a class I recommendation, along with the other recommendations from the 2017 guidelines that remained unchanged in their class of recommendation and level of evidence.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^113Tdpbp]. Circulation (2024). High credibility.

Selection of writing committee members — the Joint Committee seeks requisite content expertise and broad representation across backgrounds, including different geographic regions, sexes, races, ethnicities, intellectual perspectives/biases, and clinical practice settings, and organizations and professional societies with related interests and expertise are invited to participate as partners or collaborators.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^113TQQor]. Circulation (2024). High credibility.

Early rhythm control — With the emergence of new and consistent evidence, this guideline emphasizes the importance of early and continued management of patients with AF that should focus on maintaining sinus rhythm and minimizing AF burden.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^1137ymab]. Circulation (2006). Medium credibility.

Economic burden of atrial fibrillation — per-patient and societal costs — includes an annual cost per patient close to €3000 (approximately U.S. $3600) and a total societal burden about €13.5 billion (approximately U.S. $15.7 billion) in the European Union.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^112jgwbe]. Circulation (2006). Medium credibility.

Thromboembolism — stroke burden and risk in elderly atrial fibrillation (AF) patients are highlighted as follows: Up to 25% of strokes in patients with AF may be due to other sources, and in patients 80 to 89 y old, 36% of strokes occur in those with AF. The annual risk of stroke for octogenarians with AF is in the range of 3% to 8% per year, depending on associated stroke risk factors. Among elderly AF patients, about half have hypertension and approximately 12% harbor carotid artery stenosis, while carotid atherosclerosis is probably a relatively minor contributing epidemiological factor in AF-associated stroke.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^116dxXfR]. Circulation (2024). High credibility.

Stroke risk modifiers — Patients with AF at intermediate to low (< 2%) annual risk of ischemic stroke can benefit from consideration of factors that might modify their risk, including AF characteristics (eg, burden), nonmodifiable risk factors (sex), and dynamic or modifiable factors (blood pressure control) to inform shared decision-making discussions.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^1162XRzE]. Circulation (2024). High credibility.

Atrial fibrillation (AF) staging — The new proposed classification, using stages, recognizes AF as a disease continuum that requires a variety of strategies at the different stages, from prevention, lifestyle and risk factor modification, screening, and therapy, noting that the previous classification of AF, which was based only on arrhythmia duration, although useful, tended to emphasize therapeutic interventions.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^1154LCm4]. Circulation (2006). Medium credibility.

Prevention of postoperative atrial fibrillation (AF) — evidence synthesis: A meta-analysis of 13 randomized trials of prophylactic antiarrhythmic therapy involving 1783 patients undergoing cardiac surgery found decreases in AF incidence but less concordant effects on hospital length of stay. By meta-analysis, the effect size for prevention of stroke by prophylactic treatment for AF was not statistically significant, nor was the effect on length or cost of hospital stay, and beta blockers had the greatest magnitude of effect across 28 trials (4074 patients).

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^115bxNU8]. Circulation (2006). Medium credibility.

Atrial fibrillation — initial clinical assessment emphasizes that diagnosis is based on history and clinical examination and confirmed by electrocardiogram (ECG) recording, sometimes in the form of bedside telemetry or ambulatory Holter recordings, and that initial evaluation involves characterizing the arrhythmia pattern as paroxysmal or persistent, determining its cause, and defining associated cardiac and extracardiac factors pertinent to the etiology, tolerability, or history of prior management. A thorough history will result in a well-planned, focused workup that serves as an effective guide to therapy, and the workup can usually take place during a single outpatient encounter, with delay when the rhythm has not been specifically documented and additional monitoring is necessary. Commonly mentioned triggers include alcohol, sleep deprivation, and emotional stress, and stimulants such as caffeine or exercise may also precipitate atrial fibrillation. The physical examination may suggest atrial fibrillation on the basis of irregular pulse, irregular jugular venous pulsations, and variation in the intensity of the first heart sound or absence of a fourth sound heard previously during sinus rhythm, and examination may also disclose associated valvular heart disease, myocardial abnormalities, or heart failure.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^112K1bhu]. Circulation (2006). Medium credibility.

Atrial fibrillation — Class IIb: In patients 75 y of age and older at increased risk of bleeding but without frank contraindications, and in other patients with moderate risk factors for thromboembolism who are unable to safely tolerate anticoagulation at the standard intensity of INR 2.0 to 3.0, a lower INR target of 2.0 (range 1.6 to 2.5) may be considered for primary prevention of ischemic stroke and systemic embolism (Level of Evidence: C). When surgical procedures require interruption of oral anticoagulant therapy for longer than 1 wk in high-risk patients, unfractionated heparin may be administered or low-molecular-weight heparin given by subcutaneous injection, although the efficacy of these alternatives in this situation is uncertain (Level of Evidence: C).

---

### Newly detected atrial fibrillation: AAFP updates guideline on pharmacologic management [^116pBFKW]. American Family Physician (2017). Medium credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to rhythm control, general indications, AAFP 2017 guidelines recommend to consider initiating rhythm control in certain patients based on patient symptoms, exercise tolerance, and patient preferences.

---

### 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-thoracic Surgery (EACTS) [^111j83FH]. European Heart Journal (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to rhythm control, general indications, EACTS/ESC 2024 guidelines recommend to consider implementing a rhythm control strategy within 12 months of diagnosis in selected patients with AF at risk of thromboembolic events to reduce the risk of cardiovascular death or hospitalization.

---

### Future directions: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery [^111vGE5k]. Chest (2005). Low credibility.

The recommendations put forth in these guidelines for the management and prevention of atrial fibrillation (AF) after cardiac surgery are based on information available at the time of the final literature review. As a result, they will become dated as new information and results from new trials becomes available. The maintenance of clinical practice guidelines is an evolving process requiring the alteration of recommendations over time, based on new studies and new results. The current set of guidelines attempts not only to identify new therapeutic options for AF after cardiac surgery but also to develop a strategy to indicate how and when to update the guidelines themselves.

---

### Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians [^116XDtfT]. Annals of Internal Medicine (2003). Low credibility.

The Joint Panel of the American Academy of Family Physicians and the American College of Physicians, in collaboration with the Johns Hopkins Evidence-based Practice Center, systematically reviewed the available evidence on the management of newly detected atrial fibrillation and developed recommendations for adult patients with first-detected atrial fibrillation. The recommendations do not apply to patients with postoperative or post-myocardial infarction atrial fibrillation, patients with class IV heart failure, patients already taking antiarrhythmic drugs, or patients with valvular disease. The target physician audience is internists and family physicians dedicated to primary care. The recommendations are as follows: RECOMMENDATION 1: Rate control with chronic anticoagulation is the recommended strategy for the majority of patients with atrial fibrillation. Rhythm control has not been shown to be superior to rate control (with chronic anticoagulation) in reducing morbidity and mortality and may be inferior in some patient subgroups to rate control. Rhythm control is appropriate when based on other special considerations, such as patient symptoms, exercise tolerance, and patient preference. Grade: 2A. RECOMMENDATION 2: Patients with atrial fibrillation should receive chronic anticoagulation with adjusted-dose warfarin, unless they are at low risk of stroke or have a specific contraindication to the use of warfarin (thrombocytopenia, recent trauma or surgery, alcoholism). Grade: 1A. RECOMMENDATION 3: For patients with atrial fibrillation, the following drugs are recommended for their demonstrated efficacy in rate control during exercise and while at rest: atenolol, metoprolol, diltiazem, and verapamil (drugs listed alphabetically by class). Digoxin is only effective for rate control at rest and therefore should only be used as a second-line agent for rate control in atrial fibrillation. Grade: 1B. RECOMMENDATION 4: For those patients who elect to undergo acute cardioversion to achieve sinus rhythm in atrial fibrillation, both direct-current cardioversion (Grade: 1C+) and pharmacological conversion (Grade: 2A) are appropriate options. RECOMMENDATION 5: Both transesophageal echocardiography with short-term prior anticoagulation followed by early acute cardioversion (in the absence of intracardiac thrombus) with postcardioversion anticoagulation versus delayed cardioversion with pre- and postanticoagulation are appropriate management strategies for those patients who elect to undergo cardioversion. Grade: 2A. RECOMMENDATION 6: Most patients converted to sinus rhythm from atrial fibrillation should not be placed on rhythm maintenance therapy since the risks outweigh the benefits. In a selected group of patients whose quality of life is compromised by atrial fibrillation, the recommended pharmacologic agents for rhythm maintenance are amiodarone, disopyramide, propafenone, and sotalol (drugs listed in alphabetical order). The choice of agent predominantly depends on specific risk of side effects based on patient characteristics. Grade: 2A.

---

### Update on medical management of atrial fibrillation in the modern era [^116UKMQL]. Heart Rhythm (2009). Low credibility.

The management of atrial fibrillation involves control of the ventricular response rate, anticoagulation to reduce the risk of stroke and attempts to maintain sinus rhythm. The approach to patients with atrial fibrillation has become increasingly complex as therapeutic options have expanded. The ultimate reasons to treat atrial fibrillation include improvement in symptoms, reduction in adverse outcomes and improvement in survival. Despite increasing interest in non pharmacological approaches to treat and potentially cure atrial fibrillation, drugs remain the primary method to treat most patients. This review updates the present state-of-the-art regarding medical management of atrial fibrillation based on present and emerging evidence.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^112Cg194]. Circulation (2024). High credibility.

Atrial fibrillation primary prevention — section header "5.1. Primary Prevention" is presented.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^114aKSkj]. Circulation (2024). High credibility.

Atrial fibrillation — patient factors guiding selection between rate control and rhythm control are contrasted. Factors that favor rate control versus rhythm control include: prefers rate control versus prefers rhythm control; "Older" versus "Younger"; longer versus shorter history of AF; fewer versus more symptoms.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^111rNm1t]. Circulation (2006). Medium credibility.

Atrial fibrillation — symptoms and quality of life across strategies: The AFFIRM, RACE, PIAF (Pharmacologic Intervention in Atrial Fibrillation), and STAF (Strategies of Treatment of Atrial Fibrillation) studies found no differences in quality of life with rhythm control compared with rate control, and rhythm control in the PIAF and How to Treat Chronic Atrial Fibrillation (HOT CAFÉ) studies resulted in better exercise tolerance than rate control.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^113pv9AH]. Circulation (2006). Medium credibility.

Atrial fibrillation randomized trials — adverse outcomes by rhythm control versus rate control are tabulated with counts listed (in rate/rhythm). In AFFIRM, deaths of all causes were 666 (310/356), deaths from cardiovascular causes 167/164, deaths from noncardiovascular causes 113/165, stroke 77/80, thromboembolic events ND, and bleeding 107/96. Other trials show similar stratification, including RACE with deaths of all causes 36, cardiovascular deaths 18/18, thromboembolic events 14/21, and bleeding 12/9, and STAF with deaths of all causes 12 (8/4), cardiovascular deaths 8/3, noncardiovascular deaths 0/1, stroke 1/5, and bleeding 8/11.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^112f8iDv]. Circulation (2006). Medium credibility.

Nonvalvular atrial fibrillation — Risk factors and relative risk for ischemic stroke or systemic embolism (Table 11): Previous stroke or TIA 2.5; Diabetes mellitus 1.7; History of hypertension 1.6; Heart failure 1.4; Advanced age (continuous, per decade) 1.4. As a group, patients with nonvalvular atrial fibrillation (AF) carry about a 6-fold increased risk of thromboembolism compared with patients in sinus rhythm.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^111bkLr2]. Circulation (2006). Medium credibility.

Cardioversion of atrial fibrillation — basis for cardioversion indicates that cardioversion may be performed electively to restore sinus rhythm in patients with persistent AF, may be immediate when the arrhythmia is the main factor responsible for acute heart failure, hypotension, or worsening angina in coronary artery disease, and carries a risk of thromboembolism unless anticoagulation prophylaxis is initiated before the procedure, with risk greatest when the arrhythmia has been present for longer than 48 h.

---

### Newly detected atrial fibrillation: AAFP updates guideline on pharmacologic management [^111ofyM9]. American Family Physician (2017). Medium credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to anticoagulant therapy, general indications, AAFP 2017 guidelines recommend to initiate chronic anticoagulation in patients with AF unless they are at low risk of stroke (CHADS₂ < 2) or have specific contraindications.

---

### North American thrombosis forum, AF action initiative consensus document [^113iLajR]. The American Journal of Medicine (2016). Low credibility.

The North American Thrombosis Forum Atrial Fibrillation Action Initiative consensus document is a comprehensive yet practical briefing document focusing on stroke and bleeding risk assessment in patients with atrial fibrillation, as well as recommendations regarding anticoagulation options and management. Despite the breadth of clinical trial data and guideline recommendation updates, many clinicians continue to struggle to synthesize the disparate information available. This problem slows the uptake and utilization of updated risk prediction tools and adoption of new oral anticoagulants. This document serves as a practical and educational reference for the entire medical community involved in the care of patients with atrial fibrillation.

---

### Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? [^111MvKFg]. Journal of the American Heart Association (2014). Low credibility.

Conclusions

As highlighted in this review, registries extend knowledge of the natural history, risk factors, treatment practices, and long‐term outcomes and risks of management strategies within a truly representative population of AF patients managed in clinical practice. Together with patient database evaluations, these resources can greatly improve understanding of the needs and gaps in care for diverse patient subgroups. Though a comprehensive review of administrative databases was not within the scope of this review, increasingly relevant literature derived from mining of patient data can inform the management of patients with AF in an array of care settings.

Registry data are the means by which to determine whether patients are managed in line with evidence‐based guidelines — but they offer more than just a reflection of whether everyday practice adheres to accepted norms or ideals. Follow‐up of large numbers of patients allows assessment of long‐term outcomes and infrequent complications. There is scope to gather more information on the impact of AF and its management on quality of life as well as to provide insights into the overall health economic burden of AF. These registries have already helped shape and improve the way we manage patients, and well‐designed registries have the potential to yield hypotheses to guide future clinical and basic research.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^116iRUmv]. Circulation (2024). High credibility.

Catheter ablation as first-line therapy — Catheter ablation of AF receives a Class 1 indication as first-line therapy in selected patients, supported by randomized studies demonstrating superiority over drug therapy for rhythm control, and in view of the most recent evidence, the Class of Recommendation was upgraded.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^1175bhxx]. Circulation (2024). High credibility.

Rate control in atrial fibrillation — broad considerations: The page includes the section header titled Broad Considerations for Rate Control.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^111Q1eza]. Circulation (2024). High credibility.

Risk-based selection of oral anticoagulation — In patients diagnosed with atrial fibrillation (AF) who have an estimated annual risk of stroke or thromboembolic events ≥ 2%, selection of therapy to reduce the risk of stroke should be based on the risk of thromboembolism, regardless of whether the AF pattern is paroxysmal, persistent, long-standing persistent, or permanent (COR 1, LOE B-R). In patients with AF at risk for stroke, reevaluation of the need for and choice of stroke risk reduction therapy at periodic intervals is recommended to reassess stroke and bleeding risk, net clinical benefit, and proper dosing (COR 1, LOE B-NR).

---

### Chapter 5: guideline recommendations: which AAD and for whom? [^115Mt1mn]. The American Journal of Cardiology (2023). Medium credibility.

This chapter discusses the American College of Cardiology/American Heart Association/ Heart Rhythm Society (AHA/ACC/HRS) and European Society of Cardiology (ESC) guidelines for atrial fibrillation (AF) management with particular focus on antiarrhythmic drug (AAD) selection and the identification of individuals for whom AAD treatment is appropriate. Discussion includes AAD indications, when to start an AAD, choosing among AADs, how to minimize proarrhythmic risk, how to determine efficacy, and the use of adjuvant interventions. The indications for all AADs are based on safety; the current AHA/ACC/HRS and ESC guidelines state that the choice of AAD is based on the presence or absence of structural heart disease (SHD), coronary artery disease, or heart failure (HF), with further recommendations in the ESC guidelines based on HF type (e.g. HF with reduced ejection fraction [HFrEF] versus HF with preserved ejection fraction [HFpEF]). The chapter closes with a discussion of the lack of consistent use of guideline-directed care, with a review of supportive data from the recently reported AIM-AF survey-a multinational survey on AF management that involved both cardiologists and electrophysiologists. In AIM-AF, inappropriate drug selection in terms of suitable candidate selection and drug choice occurred with all types of drugs and in most patient groups. Most notable was the overuse of amiodarone in patients without SHD, and the widespread use of sotalol, including its use in patients with HFrEF. Chapter 5 is summarized as follows.

---

### Rate control vs rhythm control strategies in atrial fibrillation [^113F62Lu]. Progress in Cardiovascular Diseases (2005). Low credibility.

Rhythm management for atrial fibrillation is a subject of intense interest. In this review, the two main strategies for rhythm management in atrial fibrillation, the "heart rate control" strategy and the "heart rhythm control" strategy, are discussed under several headings. Some of the basic issues surrounding heart rate control and heart rhythm control and their study in clinical trials are reviewed. Seven published trials that deal with a comparison of these two strategies are reviewed in some detail. In summary, no distinct advantage of the rhythm control strategy has been identified so far. With respect to pharmacologic therapies and the type of patient studied in most of these trials, advantages seem to accrue to the rate control strategy. Those advantages include fewer adverse drug effects, fewer hospitalizations, and lower cost. Two trials studying quite different patients, and in one case quite different drug therapies, are currently in progress, and these two trials are also briefly reviewed. Current guidelines have not taken into account fully the findings of the studies described in this review, and comment is offered on the current guidelines. Finally, some of the possibilities for future research around this question are highlighted.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^116jQ8Hb]. Circulation (2006). Medium credibility.

Atrial fibrillation (AF) — recurrence and predictors: An AFFIRM substudy found that with AF recurrence, if one is willing to cardiovert and continue or change the antiarrhythmic drug, about 80% of all patients will be in sinus rhythm by the end of 1 y. Most patients with AF, except those with postoperative or self-limited AF secondary to transient or acute illness, eventually experience recurrence, and risk factors for frequent recurrence of paroxysmal AF (more than 1 episode per month) include female gender and underlying heart disease. In one study of patients with persistent AF, the 4-y arrhythmia-free survival rate was less than 10% after single-shock direct-current cardioversion without prophylactic drug therapy, with predictors of recurrences including hypertension, age over 55 y, and AF duration longer than 3 mo. Serial cardioversions and prophylactic drug therapy resulted in freedom from recurrent AF in approximately 30% of patients, and with this approach predictors of recurrence included age over 70 y, AF duration beyond 3 mo, and HF; other risk factors include LA enlargement and rheumatic heart disease.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^115qZxwd]. Circulation (2006). Medium credibility.

Laboratory evaluation in atrial fibrillation — It is important that thyroid, renal, and hepatic function, serum electrolytes, and the hemogram be measured at least once in the course of evaluating a patient with atrial fibrillation (AF), and blood tests are routine but can be abbreviated.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^112cuwmf]. Circulation (2006). Medium credibility.

Antithrombotic therapy for atrial fibrillation — risk category–based recommendations: for no risk factors the recommended therapy is Aspirin, 81 to 325 mg daily; for one moderate-risk factor the recommended therapy is Aspirin, 81 to 325 mg daily, or warfarin (INR 2.0 to 3.0, target 2.5); for any high-risk factor or more than 1 moderate-risk factor the recommended therapy is Warfarin (INR 2.0 to 3.0, target 2.5)*. Risk factor groupings are listed as Less Validated or Weaker Risk Factors (female gender, age 65 to 74 y, coronary artery disease, thyrotoxicosis), Moderate-Risk Factors (age greater than or equal to 75 y, hypertension, heart failure, LV ejection fraction 35% or less, diabetes mellitus), and High-Risk Factors (previous stroke, TIA or embolism, mitral stenosis, prosthetic heart valve*), with the footnote that If mechanical valve, target international normalized ratio (INR) greater than 2.5.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^1119sjTP]. Circulation (2006). Medium credibility.

ACC/AHA/ESC 2006 atrial fibrillation — Outpatient rhythm control and ablation options: In patients with lone atrial fibrillation (AF) without structural heart disease, initiation of propafenone or flecainide "can be beneficial on an outpatient basis in patients with paroxysmal AF who are in sinus rhythm at the time of drug initiation (Level of Evidence: B)". For selected outpatients, "Sotalol can be beneficial… if the baseline uncorrected QT interval is less than 460 ms, serum electrolytes are normal, and risk factors associated with class III drug-related proarrhythmia are not present (Level of Evidence: C)". Additionally, "Catheter ablation is a reasonable alternative to pharmacological therapy to prevent recurrent AF in symptomatic patients with little or no LA enlarge- ment (Level of Evidence: C)".

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^114N37sC]. Circulation (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to rhythm control, general indications, ACC/ACCP/AHA/HRS 2024 guidelines recommend to offer a trial of rhythm control to evaluate whether AF contributes to the reduced LV function in patients with reduced LV function and persistent (or high burden) AF.

---

### The 2020 Canadian Cardiovascular Society / Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation [^112XuvQr]. The Canadian Journal of Cardiology (2020). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to rhythm control, maintenance therapy, CCS/CHRS 2020 guidelines recommend to offer a rhythm control strategy in patients with established AF remaining symptomatic with rate control therapy or when rate control therapy is unlikely to control symptoms. Consider offering rhythm control over rate control for patients with newly diagnosed AF.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^1161NDwu]. Circulation (2024). High credibility.

Device-detected AF — Recommendations have been updated for device-detected AF, providing more prescriptive recommendations that consider the interaction between episode duration and the patient's underlying risk for thromboembolism, including considerations for AF detected via implantable devices and wearables.

---

### ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology / American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [^113D4CAt]. Circulation (2006). Medium credibility.

Acute myocardial infarction (MI) with atrial fibrillation (AF) — Class I recommendations: Direct-current cardioversion is recommended for patients with severe hemodynamic compromise or intractable ischemia, or when adequate rate control cannot be achieved with pharmacological agents in patients with acute MI and AF (Level of Evidence: C). Intravenous administration of amiodarone is recommended to slow a rapid ventricular response to AF and improve LV function in patients with acute MI (Level of Evidence: C).

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^113zvGVi]. Circulation (2024). High credibility.

Regarding medical management for atrial fibrillation, more specifically with respect to anticoagulant therapy, general indications, ACC/ACCP/AHA/HRS 2024 guidelines recommend to initiate anticoagulation to prevent stroke and systemic thromboembolism in patients with AF and an estimated annual thromboembolic risk of ≥ 2% (CHA₂DS₂-VASc score of ≥ 2 in males and ≥ 3 in females).

---

### Atrial fibrillation-clinical practice guideline… [^112Gmy64]. AAFP (2014). Low credibility.

The guideline, Pharmacologic Management of Newly Detected Atrial Fibrillation was developed by the American Academy of Family Physicians. It was approved by the Board of Directors in April 2017. See the full recommendation for further details. These recommendations are provided only as assistance for physicians making clinical decisions regarding the care of their patients. As such, they cannot substitute for the individual judgment brought to each clinical situation by the patient's family physician. As with all clinical reference resources, they reflect the best understanding of the science of medicine at the time of publication, but they should be used with the clear understanding that continued research may result in new knowledge and recommendations. These recommendations are only one element in the complex process of improving the health of America. To be effective, the recommendations must be implemented.

---

### Management of atrial fibrillation: updated guidance from the AHA… [^113NEQ5v]. AAFP (2020). Medium credibility.

Key Points for Practice
- Anticoagulation is recommended for AF at a CHA₂DS₂-VASc score of 2 for men and 3 for women without moderate or severe mitral stenosis or a mechanical valve. The score has not been validated for mitral stenosis or mechanical valves. Treatment recommendations apply to paroxysmal, persistent, and permanent AF as well as atrial flutter. In this update, the sections on anticoagulation, catheter ablation, and management of AF complicating acute coronary syndrome were modified, and new sections were added outlining weight loss and device detection of AF; however, this summary focuses on the new and revised recommendations for choosing an anticoagulant and new recommendations for preventing stroke via nonpharmacologic options and use of catheter ablation.

Direct oral anticoagulants, including dabigatran, rivaroxaban, apixaban, and edoxaban, are preferred to warfarin unless the patient has concomitant moderate or severe mitral stenosis or a mechanical heart valve. Based on new data, the recommended set-points for anticoagulation have been increased, and the previous recommendation to prescribe an anticoagulant for all patients with AF who have a history of stroke or transient ischemic attack has been removed. For patients taking warfarin, an international normalized ratio test is recommended at least every week at the start of treatment and monthly when stable within the recommended range. Warfarin is the recommended anticoagulant for patients with AF and moderate or severe mitral stenosis or a mechanical heart valve. Dabigatran should be avoided in patients with AF and a mechanical heart valve.

Renal and hepatic function should be assessed before initiating direct oral anticoagulant therapy, then at least each year thereafter. In 2017, the American Academy of Family Physicians published guidelines on AF with the American College of Physicians. These guidelines recommend using the HAS-BLED score to quantify bleeding risk like the ACCP recommendations, but recommend anticoagulant consideration for all patients with CHA₂DS₂-VASc scores of 2 or higher. — Michael Arnold, MD, Editorial Fellow. Published source: Heart Rhythm. August 2019; 16: e66–e93.

---

### Atrial fibrillation pocket guide… [^112ZyXKa]. AAFP (2017). Low credibility.

The AAFP offers concise pocket guide versions of its clinical guidelines for physicians to easily access pertinent clinical information at the point of care. AAFP pocket guides are available in print and digital formats. The AAFP guideline and pocket card contains clinical recommendations for primary care physicians to pharmacologically manage atrial fibrillation based on the available evidence. Management options for AF involve rate control, rhythm control, and/or prevention of thromboembolic events. Prior to initiating treatment, clinicians should discuss the benefits and harms of the different medications, including potential medication cost, lifestyle modifications, and risk of bleeding with anticoagulation. Tools for risk assessment and shared decision making are available. AAFP Member ID and password required.

---

### Management of atrial fibrillation: guidelines from the American… [^112Phi9t]. AAFP (2025). Medium credibility.

KEY POINTS FOR PRACTICE
- Percutaneous occlusion of the left atrial appendage reduces stroke risk and mortality with similar effectiveness as warfarin.
- Surgical exclusion of the left atrial appendage during cardiac surgery reduces stroke risk with continued anticoagulation.
- Electrical cardioversion is more effective for acute rhythm control than medications.
- Catheter ablation reduces symptoms of AF, but it recurs in up to 40% of patients. From the AFP Editors Atrial fibrillation is expected to impact 12 million people by 2030 and increase mortality risk by at least 1. 5 times. It is a chaotic, irregular atrial rhythm caused by ectopic sources in the pulmonary veins of the left atrium or in response to reentrant cardiac conduction activity from interstitial fibrosis. The American College of Cardiology and American Heart Association released guidelines for managing patients with AF.

EVALUATION Clinical evaluation of newly diagnosed AF should include transthoracic echocardiography. Testing for cardiac ischemia and pulmonary embolism is recommended only if suggested by clinical presentation. SubscribeFrom $180
- Immediate, unlimited access to all AFP content
- More than 125 CME credits/year
- AAFP app access
- Print delivery available. Issue Access $59. 95
- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available.